Pharmacokinetic Interactions Between Alcohol and Other Drugs

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1997 Aug 1

PMID 9260032

Citations 18

Authors

A G Fraser

Affiliations

Soon will be listed here.

Abstract

The frequent use of alcohol (ethanol) together with prescription drugs gives any described pharmacokinetic interaction significant clinical implications. The issue is both the effect of alcohol on the pharmacokinetics of various drugs and also the effect of those drugs on the pharmacokinetics of alcohol. This review discusses these pharmacokinetic interactions but also briefly describes some other effects of alcohol that are clinically relevant to drug prescribing. The use of several different study designs may be required before we can confidently state the presence or absence of any alcohol-drug interaction. Short term administration of alcohol in volunteers is the most common study design but studies of social drinking and prolonged moderate alcohol intake can be important in some situations. Community-based studies may illustrate the clinical relevance of any interaction. Alcohol can affect the pharmacokinetics of drugs by altering gastric emptying or liver metabolism (by inducing cytochrome P450 2E1). Drugs may affect the pharmacokinetics of alcohol by altering gastric emptying and inhibiting gastric alcohol dehydrogenase. The role of gastric alcohol dehydrogenase in the first-pass metabolism of alcohol is reviewed in this article and the arguments for and against any potential interaction between alcohol and H2 receptor antagonists are also discussed. The inhibition of the metabolism of acetaldehyde may cause disulfiram-like reactions. Pharmacodynamic interactions between alcohol and prescription drugs are common, particularly the additive sedative effects with benzodiazepines and also with some of the antihistamine drugs; other interactions may occur with tricyclic antidepressants. Alcohol intake may be a contributing factor to the disease state which is being treated and may complicate treatment because of various pathophysiological effects (e.g. impairment of gluconeogenesis and the risk of hypoglycaemia with oral hypoglycaemic agents). The combination of nonsteroidal anti-inflammatory drugs and alcohol intake increases the risk of gastrointestinal haemorrhage.

Citing Articles

Addressing Ethnicity in the Design and Evaluation of an Educational Intervention on Interindividual Variation in Pharmacokinetics.

Koenig J, Olafuyi O, Patel R Pharmacol Res Perspect. 2025; 13(1):e70073.

PMID: 39912625 PMC: 11800234. DOI: 10.1002/prp2.70073.

Alcohol Consumption Is a Coping Mechanism for Male Patients with Severe Anxiety Disorders Treated with Antidepressants Monotherapy.

Musat M, Militaru F, Udristoiu I, Mitran S, Catalin B J Clin Med. 2024; 13(9).

PMID: 38731251 PMC: 11084266. DOI: 10.3390/jcm13092723.

Age and Sex in the Development of Hepatic Encephalopathy: Role of Alcohol.

Tong X, Hussain H, Shamaladevi N, Norenberg M, Fadel A, El Hiba O Biology (Basel). 2024; 13(4).

PMID: 38666840 PMC: 11048384. DOI: 10.3390/biology13040228.

Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study.

Djochie R, Anto B, Opare-Addo M J Pharm Policy Pract. 2023; 16(1):70.

PMID: 37291618 PMC: 10249546. DOI: 10.1186/s40545-023-00577-6.

The OATH Syndemic: opioids and other substances, aging, alcohol, tobacco, and HIV.

Womack J, Justice A Curr Opin HIV AIDS. 2020; 15(4):218-225.

PMID: 32487817 PMC: 7422477. DOI: 10.1097/COH.0000000000000635.

References

Byrne A, McNeil J, Harrison P, Louis W, Tonkin A, McLean A . Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br J Clin Pharmacol. 1984; 17 Suppl 1:45S-50S. PMC: 1463259. DOI: 10.1111/j.1365-2125.1984.tb02427.x. View

Webster L, Jones D, Smallwood R . Influence of cimetidine and ranitidine on ethanol pharmacokinetics. Aust N Z J Med. 1985; 15(3):359-60. DOI: 10.1111/j.1445-5994.1985.tb04058.x. View

Hoyo-Vadillo C, Mandema J, Danhof M . Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. Life Sci. 1995; 57(4):325-33. DOI: 10.1016/0024-3205(95)00291-d. View

Lim Jr R, Gentry R, Ito D, Yokoyama H, BARAONA E, Lieber C . First-pass metabolism of ethanol is predominantly gastric. Alcohol Clin Exp Res. 1993; 17(6):1337-44. DOI: 10.1111/j.1530-0277.1993.tb05250.x. View

Brown A, Fiaterone J, Day C, Bennett M, Kelly P, James O . Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism. Gut. 1995; 37(3):413-7. PMC: 1382825. DOI: 10.1136/gut.37.3.413. View

Seitz H, Egerer G, Simanowski U, Waldherr R, Eckey R, Agarwal D . Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism. Gut. 1993; 34(10):1433-7. PMC: 1374557. DOI: 10.1136/gut.34.10.1433. View

Fraser A, Rosalki S, Gamble G, Pounder R . Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Br J Clin Pharmacol. 1995; 40(4):387-92. PMC: 1365158. DOI: 10.1111/j.1365-2125.1995.tb04561.x. View

Burnham D, Miller D, Karlstadt R, FRIEDMAN C, Palmer R . Famotidine increases plasma alcohol concentration in healthy subjects. Aliment Pharmacol Ther. 1994; 8(1):55-61. DOI: 10.1111/j.1365-2036.1994.tb00160.x. View

Brown A, Fiatarone J, Wood P, Bennett M, Kelly P, Rawlins M . The effect of gastritis on human gastric alcohol dehydrogenase activity and ethanol metabolism. Aliment Pharmacol Ther. 1995; 9(1):57-61. DOI: 10.1111/j.1365-2036.1995.tb00352.x. View

10.

Feely J, Wood A . Effects of cimetidine on the elimination and actions of ethanol. JAMA. 1982; 247(20):2819-21. View

11.

Wynne H, Wood P, Herd B, Wright P, Rawlins M, James O . The association of age with the activity of alcohol dehydrogenase in human liver. Age Ageing. 1992; 21(6):417-20. DOI: 10.1093/ageing/21.6.417. View

12.

Brophy C, Moore J, Christian P, Egger M, TAYLOR A . Variability of gastric emptying measurements in man employing standardized radiolabeled meals. Dig Dis Sci. 1986; 31(8):799-806. DOI: 10.1007/BF01296046. View

13.

Hernandez-Munoz R, Caballeria J, BARAONA E, Uppal R, Greenstein R, Lieber C . Human gastric alcohol dehydrogenase: its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol. Alcohol Clin Exp Res. 1990; 14(6):946-50. DOI: 10.1111/j.1530-0277.1990.tb01843.x. View

14.

Wittes R, Saginur R . Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ. 1995; 152(4):515-7. PMC: 1337705. View

15.

Toon S, Khan A, Holt B, Mullins F, Langley S, Rowland M . Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food. Clin Pharmacol Ther. 1994; 55(4):385-91. DOI: 10.1038/clpt.1994.46. View

16.

Pedrosa M, Russell R, Saltzman J, Golner B, Dallal G, Sepe T . Gastric emptying and first-pass metabolism of ethanol in elderly subjects with and without atrophic gastritis. Scand J Gastroenterol. 1996; 31(7):671-7. DOI: 10.3109/00365529609009148. View

17.

Pares X, Moreno A, Cederlund E, Hoog J, Jornvall J . Class IV mammalian alcohol dehydrogenase. Structural data of the rat stomach enzyme reveal a new class well separated from those already characterized. FEBS Lett. 1990; 277(1-2):115-8. DOI: 10.1016/0014-5793(90)80822-z. View

18.

Adams W . Interactions between alcohol and other drugs. Int J Addict. 1995; 30(13-14):1903-23. DOI: 10.3109/10826089509071060. View

19.

Jones A, Jonsson K . Between-subject and within-subject variations in the pharmacokinetics of ethanol. Br J Clin Pharmacol. 1994; 37(5):427-31. PMC: 1364897. DOI: 10.1111/j.1365-2125.1994.tb05709.x. View

20.

Fraser A, Hudson M, Sawyerr A, Rosalki S, Pounder R . Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. Aliment Pharmacol Ther. 1992; 6(2):267-71. DOI: 10.1111/j.1365-2036.1992.tb00270.x. View